Novel Gene Risk Score Predicts Outcomes After RYGB Surgery
A novel gene risk score, informed by machine learning, predicted weight-loss outcomes after Roux-en-Y gastric bypass (RYGB) surgery, a new analysis showed.
The findings suggested that the MyPhenome test (Phenomix Sciences) can help clinicians identify the patients most likely to benefit from bariatric procedures and at a greater risk for long-term weight regain after surgery.
'Patients with both a high genetic risk score and rare mutations in the leptin-melanocortin pathway (LMP) had significantly worse outcomes, maintaining only 4.9% total body weight loss [TBWL] over 15 years compared to up to 24.8% in other genetic groups,' Phenomix Sciences Co-founder Andres Acosta, MD, PhD, told Medscape Medical News .
The study included details on the score's development and predictive capability.
'More Precise Bariatric Care'
The researchers recently developed a machine learning-assisted gene risk score for calories to satiation (CTSGRS), which mainly involves genes in the LMP. To assess the role of the score with or without LMP gene variants on weight loss and weight recurrence after RYGB, they identified 707 patients with a history of bariatric procedures from the Mayo Clinic Biobank. Patients with duodenal switch, revisional procedures, or who used antiobesity medications or became pregnant during follow-up were excluded.
To make predictions for 442 of the patients, the team first collected anthropometric data up to 15 years after RYGB. Then they used a two-step approach: Assessing for monogenic variants in the LMP and defining participants as carriers (LMP+) or noncarriers (LMP-). Then they defined the gene risk score (CTSGRS+ or CTSGRS-).
The result was four groups: LMP+/CTSGRS+, LMP+/CTSGRS-, LMP-/CTSGRS+, and LMP-/CTSGRS-. Multiple regression analysis was used to analyze TBWL percentage (TBWL%) between the groups at different timepoints, adjusting for baseline weight, age, and gender.
At the 10-year follow-up, the LMP+/CTSGRS+ group demonstrated a significantly higher weight recurrence (regain) of TBW% compared to the other groups.
At 15 years post-RYGB, the mean TBWL% for LMP+/CTSGRS+ was -4.9 vs -20.3 for LMP+/CTSGRS-, -18.0 for LMP-/CTSGRS+, and -24.8 for LMP-/CTSGRS-.
Further analyses showed that the LMP+/CTSGRS+ group had significantly less weight loss than LMP+/CTSGRS- and LMP-/CTSGRS- groups.
Based on the findings, the authors wrote, 'Genotyping patients could improve the implementation of individualized weight-loss interventions, enhance weight-loss outcomes, and/or may explain one of the etiological factors associated with weight recurrence after RYGB.'
Acosta noted, 'We're actively expanding our research to include more diverse populations by age, sex, and race. This includes ongoing analysis to understand whether certain demographic or physiological characteristics affect how the test performs, particularly in the context of bariatric surgery.'
The team also is investigating the benefits of phenotyping for obesity comorbidities such as heart disease and diabetes, he said, and exploring whether early interventions in high-risk patients can prevent long-term weight regain and improve outcomes.
In addition, Acosta said, the team recently launched 'the first prospective, placebo-controlled clinical trial using the MyPhenome test to predict response to semaglutide.' That study is based on earlier findings showing that patients identified with a Hungry Gut phenotype lost nearly twice as much weight on semaglutide compared with those who tested negative.
Overall, he concluded, 'These findings open the door to more precise bariatric care. When we understand a patient's biological drivers of obesity, we can make better decisions about the right procedure, follow-up, and long-term support. This moves us away from a one-size-fits-all model to care rooted in each patient's unique biology.'
Potentially Paradigm-Shifting
Onur Kutlu, MD, associate professor of surgery and director of the Metabolic Surgery and Metabolic Health Program at the Miller School of Medicine, University of Miami, Miami, commented on the study for Medscape Medical News . 'By integrating polygenic risk scores into predictive models, the authors offer an innovative method for identifying patients at elevated risk for weight regain following RYGB.'
'Their findings support the hypothesis that genetic predisposition — particularly involving energy homeostasis pathways — may underlie differential postoperative trajectories,' he said. 'This approach has the potential to shift the paradigm from reactive to proactive management of weight recurrence.'
Because current options for treat weight regain are 'suboptimal,' he said, 'prevention becomes paramount. Preoperative identification of high-risk individuals could inform surgical decision-making, enable earlier interventions, and facilitate personalized postoperative monitoring and support.'
'If validated in larger, prospective cohorts, genetic risk stratification could enhance the precision of bariatric care and improve long-term outcomes,' he added. 'Future studies should aim to validate these genetic models across diverse populations and explore how integration of behavioral, psychological, and genetic data may further refine patient selection and care pathways.'
The study presented at Digestive Disease Week (DDW) 2025 was funded by Mayo Clinic and Phenomix Sciences. Gila Therapeutics and Phenomix Sciences licensed Acosta's research technologies from the University of Florida and Mayo Clinic. Acosta declared receiving consultant fees in the past 5 years from Rhythm Pharmaceuticals, Gila Therapeutics, Amgen, General Mills, BI, Currax, Nestle, Phenomix Sciences, Bausch Health, and RareDiseases, as well as funding support from the National Institutes of Health, Vivus Pharmaceuticals, Novo Nordisk, Apollo Endosurgery, Satiogen Pharmaceuticals, Spatz Medical, and Rhythm Pharmaceuticals. Kutlu declared having no conflicts of interest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
40 minutes ago
- Medscape
Merck's Potential Blockbuster Cholesterol Pill Succeeds in Late-stage Studies
(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines. The company is searching for its next blockbuster candidate as its major revenue driver, Keytruda, is expected to lose patent protection by the end of the decade. Merck's non-statin cholesterol drug, enlicitide decanoate, is being tested for the treatment of hyperlipidemia, a condition that causes elevated buildup of fat in the blood vessels and can lead to heart attacks and strokes. Enlicitide works by blocking PCSK9, a protein that plays a crucial role in regulating cholesterol levels, while statins block an enzyme the liver uses to make cholesterol. BMO Capital Markets analyst Evan Seigerman said Merck's drug could potentially provide a "multi-billion dollar opportunity" that expands the PCSK9 market beyond current injectable therapies. The drug showed meaningful reductions in LDL-C cholesterol, commonly referred to as "bad cholesterol", when compared to placebo and other oral non-statin therapies, Merck said. However, Leerink analysts have noted that Astrazeneca's AZD0780 is a "credible threat" as it has shown a 50.7% reduction in LDL-C levels during a trial. Merck has not given the details on LDL-C reduction for enlicitide. The drug was tested in patients who have a history of, or are at risk for a type of heart disease, and were treated with a statin. Shares of Merck were up 2% in premarket trading. Verve Therapeutics is also developing a gene therapy to reduce high cholesterol levels, which is expected to be used in combination with other drugs. (Reporting by Christy Santhosh in Bengaluru; Editing by Shinjini Ganguli)
Forbes
an hour ago
- Forbes
Fixing AI's Gender Bias Isn't Just Ethical—It's Good Business
As artificial intelligence (AI) tools become more embedded in daily life, they're amplifying gender biases from the real world. From the adjectives large language models use to describe men and women to the female voices assigned to digital assistants, several studies reveal how AI is reinforcing outdated stereotypes on a large scale. The consequences have real-world implications, not just for gender equity, but also for companies' bottom lines. Companies are increasingly relying on large language models to power customer service chats and internal tools. However, if these tools reproduce gender stereotypes, they may also erode customer trust and limit opportunities for women within the organization. Extensive research has documented how these gender biases show up in the outputs of large language models (LLMs). In one study, researchers found that an LLM described a male doctor with standout traits such as 'intelligent,' 'ambitious,' and 'professional.' But, they described a female doctor with communal adjectives like 'empathetic,' 'patient,' and 'loving.' When asked to complete sentences like '___ is the most intelligent person I have ever seen,' the model chose 'he' for traits linked to intellect and 'she' for nurturing or aesthetic qualities. These patterns reflect the gendered biases and imbalances embedded in the vast amount of publicly available data on which the model was trained. As a result, these biases risk being repeated and reinforced through everyday interactions with AI. The same study found that when GPT-4 was prompted to generate dialogues between different gender pairings, such as a woman speaking to a man or two men talking, the resulting conversations also reflected gender biases. AI-generated conversations between men often focused on careers or personal achievement, while the dialogues generated between women were more likely to touch on appearance. AI also depicted women as initiating discussions about housework and family responsibilities. Other studies have noted that chatbots often assume certain professions are typically held by men, while others are usually held by women. Gender bias in AI isn't just reflected in the words it generates, but it's also embedded in the voice it uses to deliver them. Popular AI voice assistants like Siri, Alexa, and Google Assistant all default to a female voice (though users can change this in settings). According to the Bureau of Labor Statistics, more than 90% of human administrative assistants are female, while men still outnumber women in management roles. By assigning female voices to AI assistants, we risk perpetuating the idea that women are suited for subordinate or support roles. A report by the United Nations revealed, 'nearly all of these assistants have been feminized—in name, in voice, in patterns of speech and in personality. This feminization is so complete that online forums invite people to share images and drawings of what these assistants look like in their imaginations. Nearly all of the depictions are of young, attractive women.' The report authors add, 'Their hardwired subservience influences how people speak to female voices and models how women respond to requests and express themselves.' 'Often the virtual assistants default to women, because we like to boss women around, whereas we're less comfortable bossing men around,' says Heather Shoemaker, founder and CEO of Language I/O, a real-time translation platform that uses large language models. Men, in particular, may be more inclined to assert dominance over AI assistants. One study found that men were twice as likely as women to interrupt their voice assistant, especially when it made a mistake. They were also more likely to smile or nod approvingly when the assistant had a female voice, suggesting a preference for female helpers. Because these assistants never push back, this behavior goes unchecked, potentially reinforcing real-world patterns of interruption and dominance that can undermine women in professional settings. Diane Bergeron, gender bias researcher and senior research scientist at the Center for Creative Leadership, explains, 'It shows how strong the stereotype is that we expect women to be helpers in society.' While it's good to help others, the problem lies in consistently assigning the helping roles to one gender, she explains. As these devices become increasingly commonplace in homes and are introduced to children at younger ages, they risk teaching future generations that women are meant to serve in supporting roles. Even organizations are naming their in-house chatbots after women. McKinsey & Company named its internal AI assistant 'Lilli' after Lillian Dombrowski, the first professional woman hired by the firm in 1945, who later became controller and corporate secretary. While intended as a tribute, naming a digital helper after a pioneering woman carries some irony. As Bergeron quipped, 'That's the honor? That she gets to be everyone's personal assistant?' Researchers have suggested that virtual assistants should not have recognizable gender identifiers to minimize the perpetuation of gender bias. Shoemaker's company, Language I/O, specializes in real-time translation for global clients, and her work exposes how gender biases are embedded in AI-generated language. In English, some gendered assumptions can go unnoticed by users. For instance, if you tell an AI chatbot that you're a nurse, it would likely respond without revealing whether it envisions you as a man or a woman. However, in languages like Spanish, French, or Italian, adjectives and other grammatical cues often convey gender. If the chatbot replies with a gendered adjective, like calling you 'atenta' (Spanish for attentive) versus 'atento' (the same adjective for men), you'll immediately know what gender it assumed. Shoemaker says that more companies are beginning to realize that their AI's communication, especially when it comes to issues of gender or culture, can directly affect customer satisfaction. 'Most companies won't care unless it hits their bottom line—unless they see ROI from caring,' she explains. That's why her team has been digging into the data to quantify the impact. 'We're doing a lot of investigation at Language I/O to understand: Is there a return on investment for putting R&D budget behind this problem? And what we found is, yes, there is.' Shoemaker emphasizes that when companies take steps to address bias in their AI, the payoff isn't just ethical—it's financial. Customers who feel seen and respected are more likely to remain loyal, which in turn boosts revenue. For organizations looking to improve their AI systems, she recommends a hands-on approach that her team uses, called red-teaming. Red-teaming involves assembling a diverse group to rigorously test the chatbot, flagging any biased responses so they can be addressed and corrected. It results in AI, which is more inclusive and user-friendly.
Yahoo
an hour ago
- Yahoo
What to know about invasive ant with fatal sting reported in multiple states
The Joro spider, Asian long-horned beetle and spotted lanternfly have company this summer. A "sneaky" invasive species that has a potentially deadly sting continues to spread across the U.S. and can be found in more than a dozen states, according to experts. Asian needle ants were first detected in the U.S. almost a century ago, but the species has continued to expand its reach, primarily throughout the Southeast, and this pest could potentially be deadly to humans, according to Dan Suiter, a professor of urban entomology at the University of Georgia. "It injects venom that can harm you. Its sting can be life threatening," Suiter recently told the university. Suiter added that people who have adverse reactions to bee and ant stings are especially vulnerable and could go into anaphylactic shock from the needle ant's sting. Anaphylaxis is a potentially life-threatening allergic reaction that can occur within seconds of being exposed to something you're allergic to, such as a sting, according to the Mayo Clinic. "If you suffer from anaphylaxis, you should really know what this ant looks like," Suiter says. "And it might be smart to carry an EpiPen." Suiter urged people to be vigilant for these invasive species, especially with ant populations peaking later this summer. What are Asian needle ants? Asian needle ants are technically known as Brachyponera chinensis – roughly translated as "short, wicked ant from China" – but their native range also includes Japan and the Koreas, according to the U.S. Forest Service. The insect was first discovered in the U.S. in 1932 in Georgia, but has only recently started to "cause problems in North America after being relatively unnoticed for many years," the U.S. Forest Service says. The pest has now been detected all the way from Washington state to Florida, according to the site as well as Mississippi State University, and the ant is recently getting more attention in Texas. Suiter says Asian needle ants are "sneaky" because they are less than a quarter of an inch long and are adept at hiding. "Unlike many invasive species that tend to colonize areas in the wake of natural or human disturbance, Asian needle ants are capable of invading undisturbed forest areas where they nest under and within logs and other debris, under stones, and in leaf litter," the U.S. Forest Service says. Environmental impacts According to Suiter, Asian needle ants wreak havoc in native environments. "They outcompete other ant species that are important to the ecology of that area," he says. Asian needle ants prey on other insects and are capable of displacing ant species that are critical for seed dispersal, according to the U.S. Forest Service. Researchers have documented large decreases in seed dispersal in forests where Asian needle ants are present. "Thus, this invasive species could have dramatic, long-term negative effects on forest understory," the service says. What should people do if they see Asian needle ants? Asian needle ants are about 0.2 inches in length, and dark brown or black with the end of the antennae and the legs being a lighter orange-brown, the U.S. Forest Service says. Other ant species can look similar, "so it takes an experienced eye to positively identify them," the service says. Suiter says that you can send a photograph or a specimen to a local University of Georgia Extension office, which can help with identification. The public can also contact a professional to come out and bait for the ants, he says. The U.S. Forest Service advises people to avoid the pest and to be especially vigilant in areas with logs and rotting or rocks were the ants can nest. "Unfortunately, as with many invasive species, it appears Asian needle ants are here to stay," the service says. Kristi Noem says "we are not going to let a repeat of 2020 happen" amid L.A. crackdown Magic in the dark: The fantastical worlds of Lightwire Theater Barbara becomes first hurricane of 2025 season to form in Pacific Ocean
